Librax

Selected form

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Librax

Property	Description
Active Ingredients	Chlordiazepoxide and Clidinium Bromide
Form	Oral Capsule
Pharmacological Class	Psychotropic Agent / Anticholinergic / Antispasmodic Combination
Common Use	Managing GI symptoms linked to nervous tension
Origin	Synthetic

What Type of Medicine is Librax and What is its Composition?

Librax is a synthetic, fixed-dose combination drug supplied as an oral capsule, combining two distinct active pharmaceutical ingredients to provide multimodal action. The two components are Chlordiazepoxide and Clidinium Bromide. Chlordiazepoxide, classified as a Benzodiazepine derivative, serves as a psychotropic agent recognized for its anxiolytic properties. Clidinium Bromide is a Quaternary Ammonium Compound that acts as an anticholinergic and antispasmodic agent. Pharmacological studies confirm the necessity of this dual formulation to simultaneously target the central nervous system and the gastrointestinal tract, a feature that distinguishes it from medications containing only one of these agents.

What is the Primary Benefit of this Dual-Action Formulation?

The primary benefit of this formulation stems from its established multimodal action, which is specifically designed to help control the combined emotional and somatic factors present in certain gastrointestinal disorders. The drug is generally employed when a patient's gut symptoms, such as cramping or spasms, are linked to underlying nervous tension or stress. The dual nature of the drug—combining an anxiolytic with an antispasmodic—is clinically recognized to support its role in alleviating functional digestive issues. Specifically, the Chlordiazepoxide component helps to alleviate associated nervous tension, while the complementary action of Clidinium Bromide directly mitigates the physical discomfort by relaxing smooth muscle spasms and reducing excessive secretions within the digestive tract, providing a comprehensive intervention.

Regulatory References

Chlordiazepoxide and Clidinium: MedlinePlus Drug Information

What side effects are possible with Librax ?

Possible Side Effects and Safety Information

The following safety information for Librax (chlordiazepoxide and clidinium bromide) is based on official government regulatory labeling.

Common and Expected Adverse Reactions

The most commonly reported adverse reactions are often mild and reflect the drug's properties. These may include drowsiness, dry mouth, blurred vision, nausea, and constipation.

Adverse effects are categorized by the affected body system (System-Organ Class) in regulatory documents, including effects on the Nervous System (e.g., dizziness, confusion), Gastrointestinal system, Eye disorders, and Skin and Subcutaneous Tissue (e.g., rash, edema).

Serious Adverse Reactions

Although rare, certain severe adverse reactions are documented and require immediate attention. These include blood disorders (such as agranulocytosis or leukopenia), jaundice, and paradoxical reactions such as excitement or acute rage. The label also warns of the risk of respiratory depression and death, particularly when used with central nervous system depressants like opioids.

Population-Specific Safety Statements

Specific caution is advised for certain patient groups. Older adults may be more susceptible to adverse effects like confusion, oversedation, and anticholinergic effects such as urinary retention. Use during pregnancy is associated with risks of neonatal withdrawal symptoms and is contraindicated in the first trimester due to the potential for congenital malformations.

Dependence and Safety Restrictions

Continued use may lead to physical dependence, and abrupt discontinuation can precipitate severe, potentially life-threatening withdrawal reactions. Librax is contraindicated in patients diagnosed with glaucoma or those with prostatic hypertrophy or other forms of bladder neck obstruction.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory descriptions of Librax (chlordiazepoxide and clidinium bromide) overdose delineate a dual manifestation profile, stemming from the central nervous system (CNS) depression of chlordiazepoxide and the anticholinergic effects of clidinium bromide.

Documented Manifestations and Severe Outcomes

Clinical signs of overdose may include severe somnolence, confusion, and diminished reflexes. Anticholinergic manifestations, which may be prominent, include excessive dryness of the mouth, blurred vision, and urinary hesitancy.

The official labeling notes the risk of severe, life-threatening outcomes, including profound sedation, respiratory depression, hypotension, and coma, particularly in cases involving concomitant ingestion of alcohol or other CNS depressants.

Regulatory-Mandated Emergency Actions

Government guidance requires that individuals seek immediate medical attention for any suspected overdose. Emergency services should be contacted for severe symptoms such as slowed or difficult breathing or profound sedation.

Management is primarily symptomatic and supportive, involving the mandated monitoring of respiration, pulse, and blood pressure. While no specific single antidote is documented, specific procedures like immediate gastric lavage and maintaining an adequate airway are cited as necessary interventions. Regulatory documents also note that elderly and debilitated patients may be at higher risk for severe outcomes, such as oversedation and confusion, in an overdose scenario.

Therapeutic Uses of Librax

Quick Facts: Librax

Adjunctive therapy for: Irritable Bowel Syndrome (IBS)
Adjunctive therapy for: Peptic Ulcer
Adjunctive therapy for: Acute Enterocolitis
Primary role: To assist in the management of emotional and physical factors in gastrointestinal conditions.

What Librax Treats: Main Uses and Benefits

Librax (chlordiazepoxide and clidinium bromide) is a prescription combination medication indicated for use as adjunctive therapy in the management of certain gastrointestinal disorders. This means it is administered alongside other recommended treatments.

Therapeutic Domains

Irritable Bowel Syndrome (IBS): The medication is utilized in the care of irritable bowel syndrome, which may present as irritable colon, spastic colon, or mucous colitis. The components aim to mitigate associated symptoms.
Peptic Ulcer: It is employed as an add-on treatment for peptic ulcer, a condition involving sores that develop on the lining of the stomach or small intestine.
Acute Enterocolitis: The combination formulation is also indicated for use in managing acute enterocolitis, which involves inflammation of the colon and small intestine.

The therapeutic approach is intended to address the emotional and physical factors that often accompany these digestive conditions. Its use as an adjunctive measure is consistent with the established indications for this drug.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Librax

Official regulatory documentation defines the eligibility for Librax (chlordiazepoxide and clidinium bromide) through strict population contraindications and restrictions.

Classification	Population/Condition
Contraindicated	Hypersensitivity to components, Glaucoma, Obstructive Uropathy (e.g., prostatic hypertrophy), Obstructive Gastrointestinal Disease (e.g., paralytic ileus), Myasthenia Gravis [1.1, 1.4].
Age Restriction	Not established as safe or effective in the pediatric population (under 18). Use is generally restricted to adults [1.2].
Life Stage	Use is generally contraindicated in pregnancy and not recommended during lactation [1.4, 3.1].
Conditional Use	Patients with impaired hepatic or renal function require caution [4.2]. Similarly, patients with a history of substance abuse or dependence or severe mental illness should only use the medicine with caution [1.1, 4.4].

These eligibility rules are primarily determined by the potential for the anticholinergic component to affect smooth muscle and ocular pressure, and the known risks of dependence and CNS effects associated with the benzodiazepine component. Use in older adults requires that the dosage be limited to the lowest effective amount due to heightened sensitivity [1.1, 2.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Librax (chlordiazepoxide and clidinium bromide) focuses on interactions categorized by pharmacodynamic and pharmacokinetic effects, with emphasis on additive CNS depression risks.

Pharmacodynamic Interactions

Co-administration with opioid analgesics is associated with a severe risk of profound sedation, respiratory depression, coma, and death due to additive Central Nervous System (CNS) depressant effects. This additive risk also applies to other CNS depressants, including sedatives, hypnotics, and anxiolytics. Certain psychotropic agents, such as MAO Inhibitors and phenothiazines, are noted as potentiating compounds that require careful consideration. The use of other anticholinergic drugs may lead to compounded anticholinergic effects from the clidinium bromide component.

Pharmacokinetic and Substance Interactions

Alcohol (Ethanol) ingestion must be avoided, as it may result in potentially fatal additive CNS depressant effects, including profound sedation.
Agents that inhibit hepatic enzymes (specifically CYP3A4 and CYP2D6) may lead to an increase in the plasma concentration of the chlordiazepoxide component.
Agents that induce hepatic enzymes (specifically CYP3A4) may lead to a decrease in the plasma concentration of the chlordiazepoxide component.

Population-Specific Interaction Notes

Interaction-related effects, such as oversedation, ataxia, and confusion, are documented as being heightened in geriatric or debilitated patients, which necessitates limiting dosage to the smallest effective amount according to regulatory instructions.

Mechanism of Action

The action of Librax is mediated by two pharmacologically distinct components, chlordiazepoxide and clidinium, acting on the central nervous system (CNS) and the peripheral nervous system (PNS), respectively. Chlordiazepoxide, a benzodiazepine, mediates its effects by allosterically modulating the GABAA receptor complex. Binding to a specific site on the receptor increases the frequency of chloride ion channel opening. The resulting net influx of Cl^- ions hyperpolarizes the postsynaptic neuron, leading to a decrease in generalized neuronal excitability. Clidinium, an anticholinergic agent, functions as a competitive antagonist at peripheral muscarinic acetylcholine receptors. This interaction blocks the binding of the neurotransmitter acetylcholine, particularly within the enteric nervous system. This antagonism reduces cholinergic transmission to the smooth muscle cells of the gut wall. The dual action modulates both CNS activity and gastrointestinal smooth muscle motility and secretion concurrently.

Dosage and Administration Information

Instruction Map: How to use Librax

This map summarizes the instructions for using Librax (chlordiazepoxide hydrochloride and clidinium bromide).

Property	Instruction
Route of administration	Oral administration only.
Dosing schedule	Standard Adult Dose: 1 or 2 capsules per dose. Dosing is individualized to achieve maximum benefit.
Timing in relation to meals (if applicable)	Administered before meals and at bedtime (hs).
Preparation requirements (if applicable)	The capsule must be swallowed whole; it should not be crushed, broken, or chewed.
Age-group administration rules	Older and Debilitated Adults: The initial daily dose should not exceed 2 capsules per day. Dosage is increased gradually and limited to the smallest effective amount.
Special procedural conditions	Discontinuation: The dosage must be tapered gradually when the medicine is being discontinued to mitigate risks associated with abrupt cessation.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Multiple times daily (3 or 4 times daily)
Use-context constraints	Fixed timing relative to food intake and sleep.

Resulting Procedural Structure

The use protocol is defined by an individualized regimen of oral capsules taken multiple times daily according to a fixed time pattern relative to meals and sleep. The typical dosage is 1 or 2 capsules, three or four times per day. The capsule must be swallowed whole to ensure proper delivery of the combined ingredients. This protocol mandates specific dose limits for older and debilitated adults, who should begin with no more than 2 capsules daily, and requires the dosage to be gradually reduced when the medicine is discontinued. These requirements establish the standardized boundaries for the drug's proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Librax

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research exploring Librax has historically focused on its evaluation in Irritable Bowel Syndrome (IBS), with studies including populations where gut symptoms were linked to nervous tension. Studies conducted include short-term Randomized Controlled Trials (RCTs), where the combination drug was compared against an inactive substance (placebo). Researchers primarily examined patient-reported outcomes describing perceived discomfort, such as the frequency and severity of abdominal pain and cramping. Findings described patterns observed in the studies where the combination was evaluated for outcomes related to measures of physical discomfort over the short observation intervals.

The evidence for IBS indicates variability in outcomes reported across studies. Long-term effects are not fully established, meaning there is limited information for long-term outcomes or how often patients need to continue using the drug to maintain the observed changes. Data for certain specific IBS subgroups remain insufficient, and research is ongoing.

Evidence for Adjunctive Use in Peptic Ulcer and Acute Enterocolitis

The combination drug was studied for use as an adjunctive therapy (an addition to other main treatments), a status consistent with regulatory indications, in two other conditions: Peptic Ulcer and Acute Enterocolitis. For Peptic Ulcer, research was conducted during periods of increased symptom activity in adults receiving established treatments. Research has explored changes in reported pain measurements during the acute treatment period. The evidence quality varies across studies, and its evaluation has focused on symptomatic outcomes.

For Acute Enterocolitis, research examined the drug's role in conditions characterized by fluctuating manifestations, focusing on the management of acute cramping and spasm. Formal, contemporary controlled studies specifically for this acute inflammatory state are less commonly published. Findings documented in official sources reflect research that evaluated symptomatic outcomes related to physical discomfort, and certainty remains low due to the limited number of large-scale controlled trials.

Summary of Research Gaps and Uncertainties

Scientific evaluations and regulatory reviews point to several areas where evidence is considered limited or where more research is needed. Evidence quality varies across studies, and some of the core research is historical, reflecting the standard clinical trial methodologies used at the time of their publication. Comparative evidence, which would clarify how the combination compares to newer, single-agent therapies or non-pharmacological approaches, is lacking or inconsistent. Sample sizes were modest in some key studies. Overall, research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about this fixed-dose combination.

Frequently Asked Questions (FAQ)

Common questions about Librax (FAQ)

Q: What is Librax used for?

A: Librax is a combination medication used to treat the symptoms of irritable bowel syndrome (IBS). It is typically prescribed for patients who also need to manage anxiety or tension related to their gut symptoms. It contains two drugs: chlordiazepoxide (a benzodiazepine) and clidinium (an anticholinergic).

Q: How does Librax work?

A: Librax works through its two active ingredients:

Chlordiazepoxide is a sedative that helps decrease anxiety and tension, which can often worsen IBS symptoms.
Clidinium is an anticholinergic (or antispasmodic) that works by slowing the natural movements of the gut and reducing stomach acid, helping to relieve cramps and spasms associated with IBS.

Q: Is Librax safe to take long-term?

A: Librax is generally intended for short-term use because of its component, chlordiazepoxide, which has a risk of dependence and withdrawal symptoms when used for long periods. Your healthcare provider will determine the appropriate duration of treatment based on your symptoms and overall health.

Q: What are the common side effects of Librax?

A: Common side effects of Librax may include:

Drowsiness or sedation
Dry mouth
Blurred vision
Constipation
Mild nausea

Because of the drowsiness, it is important to avoid driving or operating heavy machinery until you know how this medication affects you.

Q: Can I drink alcohol while taking Librax?

A: No, you should strictly avoid alcohol while taking Librax. Alcohol can significantly increase the sedative effects of the chlordiazepoxide component in Librax, leading to excessive drowsiness, profound sedation, difficulty breathing, or other dangerous side effects.

Q: What should I do if I miss a dose of Librax?

A: If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once to make up for a missed dose.

Q: Can Librax be stopped suddenly?

A: No, you should not stop taking Librax suddenly, especially if you have been taking it regularly for more than a few weeks. Abruptly stopping the medication can lead to withdrawal symptoms because of the chlordiazepoxide component. Always talk to your healthcare provider about how to safely and gradually stop the medication if it is no longer needed.

How should Librax be stored and disposed of?

How to Store and Dispose of Librax

Official regulatory guidelines define specific storage and disposal requirements for Librax capsules.

Requirement Area	Official Guidelines
Storage Temperature	Store at room temperature, specifically between 15°C and 30°C (59°F and 86°F).
Environmental Protection	Keep the capsules protected from moisture, excess heat, and light. Do not freeze.
Packaging	Keep the medication in its original container and ensure the lid is tightly closed.
Security	As Librax contains a Schedule IV controlled substance, it must be stored securely and kept strictly out of the reach of children and pets.
Disposal	Do not dispose of unused or expired medicine in household trash or down a sink/toilet. Patients should consult a healthcare provider or utilize an official drug take-back program for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z